LifeMD/$LFMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LifeMD
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
Ticker
$LFMD
Sector
Primary listing
Industry
Health Care Technology
Headquarters
Employees
306
Website
LifeMD Metrics
BasicAdvanced
$473M
-
-$0.33
2.41
-
Price and volume
Market cap
$473M
Beta
2.41
52-week high
$15.84
52-week low
$3.99
Average daily volume
1.5M
Financial strength
Current ratio
0.821
Quick ratio
0.732
Long term debt to equity
-3,311.367
Total debt to equity
-6,390.457
Interest coverage (TTM)
-3.19%
Profitability
EBITDA (TTM)
-5.865
Gross margin (TTM)
87.99%
Net profit margin (TTM)
-4.58%
Operating margin (TTM)
-3.18%
Effective tax rate (TTM)
-4.12%
Revenue per employee (TTM)
$760,000
Management effectiveness
Return on assets (TTM)
-6.88%
Return on equity (TTM)
-2,243.07%
Valuation
Price to revenue (TTM)
1.876
Price to book
-194.58
Price to tangible book (TTM)
-24.59
Price to free cash flow (TTM)
7,346.507
Free cash flow yield (TTM)
0.01%
Free cash flow per share (TTM)
0.001
Growth
Revenue change (TTM)
43.07%
Earnings per share change (TTM)
-55.34%
3-year revenue growth (CAGR)
31.16%
10-year revenue growth (CAGR)
76.23%
3-year earnings per share growth (CAGR)
-47.31%
10-year earnings per share growth (CAGR)
20.28%
What the Analysts think about LifeMD
Analyst ratings (Buy, Hold, Sell) for LifeMD stock.
Bulls say / Bears say
LifeMD's collaboration with Medifast, including a $20 million investment, positions the company to tap into the growing medically supported weight loss market, projected to reach $100 billion by 2030. (nasdaq.com)
The partnership with Novo Nordisk to offer Wegovy® at a discounted rate enhances LifeMD's weight management program, potentially attracting a larger customer base seeking affordable weight loss solutions. (stocktitan.net)
LifeMD's acquisition of Optimal Human Health MD marks its strategic entry into the women's health market, expanding its service offerings and addressing significant gaps in women's healthcare. (stocktitan.net)
The discontinuation of Medifast's quarterly cash dividend, effective immediately, may signal financial challenges or a shift in capital allocation priorities that could impact LifeMD's partnership. (nasdaq.com)
Analyst coverage includes a 'neutral' rating with a $7.00 price target, suggesting limited upside potential and possible concerns about LifeMD's valuation. (marketbeat.com)
The sale of 25,000 shares by CEO Justin Schreiber could be perceived as a lack of confidence in the company's future performance, potentially influencing investor sentiment negatively. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
LifeMD Financial Performance
Revenues and expenses
LifeMD Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for LifeMD stock?
LifeMD (LFMD) has a market cap of $473M as of August 01, 2025.
What is the P/E ratio for LifeMD stock?
The price to earnings (P/E) ratio for LifeMD (LFMD) stock is 0 as of August 01, 2025.
Does LifeMD stock pay dividends?
No, LifeMD (LFMD) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next LifeMD dividend payment date?
LifeMD (LFMD) stock does not pay dividends to its shareholders.
What is the beta indicator for LifeMD?
LifeMD (LFMD) has a beta rating of 2.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.